$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

$kpti Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000110465914078971 Filed on November 10, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$16.00K	$21.00K	$0.00
YoY Change	-23.81%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.920M	$3.810M	$1.580M
YoY Change	138.71%	141.14%	135.82%
% of Gross Profit
Research & Development	$20.04M	$15.95M	$7.738M
YoY Change	106.81%	106.14%	157.93%
% of Gross Profit
Depreciation & Amortization	$130.0K	$100.0K	$40.00K
YoY Change	333.33%	150.0%	33.33%
% of Gross Profit
Operating Expenses	$25.96M	$19.77M	$9.321M
YoY Change	113.31%	112.05%	154.05%
Operating Profit	-$25.94M	-$19.74M	-$9.321M
YoY Change	113.55%	111.82%	156.42%
Interest Expense	$40.00K	$20.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$14.00K	$20.00K
YoY Change	600.0%
Pretax Income	-$25.93M	-$19.72M	-$9.320M
YoY Change	113.42%	111.59%	156.04%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$25.93M	-$19.72M	-$9.320M
YoY Change	113.4%	111.63%	156.04%
Net Earnings / Revenue	-162050.0%	-93923.81%
Basic Earnings Per Share
Diluted Earnings Per Share	-$793.2K	-$605.7K	-$3.669M
COMMON SHARES
Basic Shares Outstanding	32.70M shares	32.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$205.7M	$227.1M	$52.90M
YoY Change	31.86%	329.3%
Cash & Equivalents	$150.6M	$227.1M	$52.93M
Short-Term Investments	$55.10M
Other Short-Term Assets	$2.000M	$4.200M	$700.0K
YoY Change	0.0%	500.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$207.8M	$231.3M	$53.60M
YoY Change	31.52%	331.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.754M	$2.734M	$200.0K
YoY Change	1047.5%	1267.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$8.700M
YoY Change
Other Assets	$774.0K	$675.0K	$2.100M
YoY Change	2480.0%	-67.86%
Total Long-Term Assets	$12.59M	$3.809M	$2.300M
YoY Change	4561.48%	65.61%
TOTAL ASSETS
Total Short-Term Assets	$207.8M	$231.3M	$53.60M
Total Long-Term Assets	$12.59M	$3.809M	$2.300M
Total Assets	$220.3M	$235.2M	$55.90M
YoY Change	39.25%	320.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.288M	$2.102M	$1.700M
YoY Change	261.38%	23.65%
Accrued Expenses	$5.825M	$3.649M	$1.900M
YoY Change	398.72%	92.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.30M	$6.234M	$4.000M
YoY Change	273.66%	55.85%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.200M	$1.100M
YoY Change
Total Long-Term Liabilities	$1.200M	$1.100M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.30M	$6.234M	$4.000M
Total Long-Term Liabilities	$1.200M	$1.100M	$0.00
Total Liabilities	$13.54M	$7.351M	$4.000M
YoY Change	311.39%	83.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$138.3M
YoY Change	121.11%
Common Stock	$345.2M	$3.000K
YoY Change	11505533.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$206.8M	$227.8M	$51.90M
YoY Change
Total Liabilities & Shareholders Equity	$220.3M	$235.2M	$55.90M
YoY Change	39.25%	320.67%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$25.93M	-$19.72M	-$9.320M
YoY Change	113.4%	111.63%	156.04%
Depreciation, Depletion And Amortization	$130.0K	$100.0K	$40.00K
YoY Change	333.33%	150.0%	33.33%
Cash From Operating Activities	-$12.77M	-$16.23M	-$8.900M
YoY Change	26.69%	82.36%	145.18%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$2.290M	-$30.00K
YoY Change	200.0%	7533.33%	0.0%
Acquisitions
YoY Change
Other Investing Activities	-$63.80M	$0.00
YoY Change
Cash From Investing Activities	-$63.89M	-$2.290M	-$30.00K
YoY Change	212866.67%	7533.33%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$112.8M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	150.0K	113.3M	44.18M
YoY Change	-99.87%	156.54%	1667.2%
NET CHANGE
Cash From Operating Activities	-12.77M	-16.23M	-8.900M
Cash From Investing Activities	-63.89M	-2.290M	-30.00K
Cash From Financing Activities	150.0K	113.3M	44.18M
Net Change In Cash	-76.51M	94.82M	35.25M
YoY Change	-174.25%	168.99%	-3138.79%
FREE CASH FLOW
Cash From Operating Activities	-$12.77M	-$16.23M	-$8.900M
Capital Expenditures	-$90.00K	-$2.290M	-$30.00K
Free Cash Flow	-$12.68M	-$13.94M	-$8.870M
YoY Change	26.17%	57.16%	146.39%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3649000	USD
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	14000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3097000	USD
CY2014Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	363000	USD
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2734000	USD
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	167000	USD
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1228000	USD
CY2014Q3	kpti	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	1660000	USD
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	594000	USD
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1583000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	158226000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32614387	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29587258	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32614387	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29587258	shares
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	21000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15951000	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3814000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	19765000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-19744000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19724000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32558646	shares
	kpti	Noncash Consulting Expense NoncashConsultingExpense	88000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7738000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	9321000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9321000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2042000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9321000	USD
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2544587	shares
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9321000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	214000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40089000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10028000	USD
	us-gaap	Operating Expenses OperatingExpenses	50117000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-49903000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	54000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49849000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.66
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30619074	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18763000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3405000	USD
	us-gaap	Operating Expenses OperatingExpenses	22168000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-21802000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21801000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-9.11
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2392589	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21801000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	106000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1769000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	95000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	645000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	673000	USD
	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	1156000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-66000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20212000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2735000	USD
	us-gaap	Increase In Restricted Cash IncreaseInRestrictedCash	400000	USD
	us-gaap	Stock Issued1 StockIssued1	13980000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	112972000	USD
	kpti	Proceeds From Sale Of Convertible Preferred Stock Net Of Issuance Costs ProceedsFromSaleOfConvertiblePreferredStockNetOfIssuanceCosts	72434000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	72774000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	71157000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	52537000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	391000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52928000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-135000	USD
CY2014Q3	kpti	Operating Leases Allowance For Improvements OperatingLeasesAllowanceForImprovements	1000000	USD
CY2014Q1	us-gaap	Security Deposit SecurityDeposit	400000	USD
CY2014Q1	kpti	Security Deposit Which May Be Reduced In Future SecurityDepositWhichMayBeReducedInFuture	200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3135000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19724000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49849000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	191000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9649000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2233000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	362000	USD
	kpti	Increase Decrease In Accrued Liabilities And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherLiabilities	2601000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-65000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-38680000	USD
CY2014Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	142000	USD
CY2014Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1117000	USD
CY2014Q3	us-gaap	Liabilities Liabilities	7351000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	3292000	USD
	kpti	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	1259000	USD
CY2014Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	29933
CY2014Q1	kpti	Operating Lease Scheduled Rent Payments Due OperatingLeaseScheduledRentPaymentsDue	5600000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P161D
CY2014Q1	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	506000	USD
CY2014Q1	us-gaap	Operating Leases Rent Expense Contingent Rentals OperatingLeasesRentExpenseContingentRentals	898000	USD
CY2014Q1	kpti	Lessee Leasing Arrangements Operating Leases Number Of Additional Lease Term LesseeLeasingArrangementsOperatingLeasesNumberOfAdditionalLeaseTerm	1	item
CY2014Q1	kpti	Lessee Leasing Arrangements Operating Leases Additional Extension Term LesseeLeasingArrangementsOperatingLeasesAdditionalExtensionTerm	P5Y
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-25000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3292000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
	dei	Entity Registrant Name EntityRegistrantName	Karyopharm Therapeutics Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001503802
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32700563	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4215000	USD
CY2014Q3	us-gaap	Assets Current AssetsCurrent	231346000	USD
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	675000	USD
CY2014Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	400000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227131000	USD
CY2014Q3	us-gaap	Assets Assets	235155000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1982000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	157956000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	30000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155974000	USD
CY2013Q4	us-gaap	Assets Assets	158226000	USD
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2102000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1740000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	79000	USD
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	327000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	305000	USD
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6234000	USD
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	235155000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	366000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-50000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	112837000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	340000	USD
CY2014Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2447247	shares
CY2014Q3	us-gaap	Share Price SharePrice	42.50
CY2014Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	397087	shares
CY2014Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	112800000	USD
CY2014Q3	kpti	Stock Issuance Costs StockIssuanceCosts	794000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2014Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	340219000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217500000	USD
CY2014Q3	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	112418000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	62569000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	227804000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	154934000	USD

Files In Submission

Name	View Source	Status
0001104659-14-078971-index-headers.html	Edgar Link	pending
0001104659-14-078971-index.html	Edgar Link	pending
0001104659-14-078971.txt	Edgar Link	pending
0001104659-14-078971-xbrl.zip	Edgar Link	pending
a14-19918_110q.htm	Edgar Link	pending
a14-19918_1ex31d1.htm	Edgar Link	pending
a14-19918_1ex31d2.htm	Edgar Link	pending
a14-19918_1ex32d1.htm	Edgar Link	pending
a14-19918_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
kpti-20140930.xml	Edgar Link	completed
kpti-20140930.xsd	Edgar Link	pending
kpti-20140930_cal.xml	Edgar Link	unprocessable
kpti-20140930_def.xml	Edgar Link	unprocessable
kpti-20140930_lab.xml	Edgar Link	unprocessable
kpti-20140930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti

2014 Q4 Form 10-Q Financial Statement

#000110465914078971 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI Karyopharm Therapeutics Inc. Stock $kpti

2014 Q4 Form 10-Q Financial Statement

#000110465914078971 Filed on November 10, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPTI
Karyopharm Therapeutics Inc. Stock $kpti